$AGIO
AGIOS PHARMACEUTICALS, INC.

2016 Q2 Form 10-Q Financial Statement

#000119312516582822 Filed on May 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $6.978M $31.28M $34.20M
YoY Change -47.21% -8.54% 306.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.64M $10.84M $6.950M
YoY Change 41.55% 55.97% 111.25%
% of Gross Profit
Research & Development $50.80M $44.04M $32.44M
YoY Change 39.48% 35.74% 86.38%
% of Gross Profit
Depreciation & Amortization $1.400M $1.246M $370.0K
YoY Change 75.0% 236.76% 11.45%
% of Gross Profit
Operating Expenses $63.45M $54.88M $39.40M
YoY Change 39.9% 39.29% 90.37%
Operating Profit -$56.47M -$23.59M -$5.195M
YoY Change 75.74% 354.17% -57.71%
Interest Expense $520.0K $400.0K $240.0K
YoY Change 116.67% 66.67% 500.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$55.95M -$23.20M -$4.960M
YoY Change 75.39% 367.74% -59.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$55.95M -$23.20M -$4.957M
YoY Change 75.42% 367.98% -59.53%
Net Earnings / Revenue -801.85% -74.16% -14.49%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.474M -$612.8K -$133.3K
COMMON SHARES
Basic Shares Outstanding 37.92M shares 37.85M shares 37.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $465.4M $312.9M $344.7M
YoY Change 25.85% -9.23% 112.43%
Cash & Equivalents $234.0M $39.04M $35.26M
Short-Term Investments $231.3M $273.9M $309.5M
Other Short-Term Assets $8.900M $9.200M $5.500M
YoY Change 93.48% 67.27% -26.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $484.2M $329.5M $364.1M
YoY Change 24.09% -9.52% 111.2%
LONG-TERM ASSETS
Property, Plant & Equipment $25.13M $22.95M $14.30M
YoY Change 30.04% 60.52% 314.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $46.90M $42.90M $95.30M
YoY Change -26.95% -54.98% 1806.0%
Other Assets $1.382M $838.0K $640.0K
YoY Change 109.39% 30.94% 37.04%
Total Long-Term Assets $73.44M $66.65M $110.2M
YoY Change -12.81% -39.52% 1060.56%
TOTAL ASSETS
Total Short-Term Assets $484.2M $329.5M $364.1M
Total Long-Term Assets $73.44M $66.65M $110.2M
Total Assets $557.6M $396.1M $474.3M
YoY Change 17.54% -16.49% 160.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.45M $13.75M $12.64M
YoY Change 106.96% 8.75% 186.56%
Accrued Expenses $14.41M $12.25M $15.60M
YoY Change 24.43% -21.51% 306.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.26M $45.06M $36.38M
YoY Change 48.82% 23.85% 6.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $201.3M $18.70M $11.10M
YoY Change 705.2% 68.47% 369900.0%
Total Long-Term Liabilities $201.3M $18.70M $11.10M
YoY Change 705.2% 68.47% 369900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.26M $45.06M $36.38M
Total Long-Term Liabilities $201.3M $18.70M $11.10M
Total Liabilities $268.5M $63.70M $47.50M
YoY Change 282.48% 34.11% 39.36%
SHAREHOLDERS EQUITY
Retained Earnings -$363.8M -$307.9M -$171.9M
YoY Change 78.52% 79.1% 36.77%
Common Stock $652.6M $640.2M $598.5M
YoY Change 7.38% 6.96% 142.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $289.1M $332.4M $426.8M
YoY Change
Total Liabilities & Shareholders Equity $557.6M $396.1M $474.3M
YoY Change 17.54% -16.49% 160.75%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$55.95M -$23.20M -$4.957M
YoY Change 75.42% 367.98% -59.53%
Depreciation, Depletion And Amortization $1.400M $1.246M $370.0K
YoY Change 75.0% 236.76% 11.45%
Cash From Operating Activities $157.8M -$19.00M -$25.60M
YoY Change 3845.0% -25.78% -5.19%
INVESTING ACTIVITIES
Capital Expenditures -$2.800M $2.533M $3.797M
YoY Change -74.31% -33.29% 29107.69%
Acquisitions
YoY Change
Other Investing Activities $38.50M -$12.30M $48.80M
YoY Change -10.67% -125.2% -496.75%
Cash From Investing Activities $35.70M -$14.80M $45.00M
YoY Change 10.87% -132.89% -465.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 1.100M 1.800M
YoY Change 36.36% -38.89% 200.0%
NET CHANGE
Cash From Operating Activities 157.8M -19.00M -25.60M
Cash From Investing Activities 35.70M -14.80M 45.00M
Cash From Financing Activities 1.500M 1.100M 1.800M
Net Change In Cash 195.0M -32.70M 21.20M
YoY Change 422.79% -254.25% -154.78%
FREE CASH FLOW
Cash From Operating Activities $157.8M -$19.00M -$25.60M
Capital Expenditures -$2.800M $2.533M $3.797M
Free Cash Flow $160.6M -$21.53M -$29.40M
YoY Change 977.85% -26.75% 8.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37921791 shares
CY2015Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
34 Securities
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35256000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5318350 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
45.03
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37899242 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
45.40
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2285769 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37899242 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.13
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4956261 shares
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
640124000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
266000
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3451000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
332373000
CY2016Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1126000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
89000
CY2016Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2539000
CY2016Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
16740000
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16523000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
13746000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12247000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-307878000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
396117000
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1949000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
38000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
45055000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
58510000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
343564000
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
838000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
67184000
CY2016Q1 us-gaap Assets
Assets
396117000
CY2016Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
571000
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
101600000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22950000
CY2016Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
42860000
CY2016Q1 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
6800000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
329469000
CY2016Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
26845000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
273859000
CY2016Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
6814000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9190000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39035000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72522000
CY2016Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q1 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
7404000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14031000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4618697 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.45
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37696502 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
74 Securities
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37696502 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
630078000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1314000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7005000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
345118000
CY2015Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
228000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-318000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2479000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17360000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19665000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14748000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15996000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284680000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
420065000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4699000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52888000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
363475000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
611000
CY2015Q4 us-gaap Assets
Assets
420065000
CY2015Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3374000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
207400000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23220000
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
58905000
CY2015Q4 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
8200000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
337329000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
59332000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
245238000
CY2015Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
8225000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8728000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71764000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153573000
CY2015Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2015Q4 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
7449000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
6000000
CY2014Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
1500000
CY2014 agio Initial Agreement Period
InitialAgreementPeriod
P5Y
CY2014 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2014 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2016-04
CY2014 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2014 agio Extended Agreement Period
ExtendedAgreementPeriod
P6Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M27D
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25585000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171 pure
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4559834 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7035 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37214747 shares
CY2015Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
34202000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3797000
CY2015Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
4573000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4957000
CY2015Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8218000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
708000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
207000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5195000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-172000
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
248000
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4709000
CY2015Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
524000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
238000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6602000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
35526000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5060000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-31393000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21225000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
39397000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
44988000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1822000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32443000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2029000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5060000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1574000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6954000
CY2015Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3841000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
84311000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2665000
CY2015Q1 us-gaap Depreciation
Depreciation
370000
CY2015Q1 agio Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-4400000
CY2015Q1 agio Collaboration Revenue
CollaborationRevenue
34200000
CY2015Q1 agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
60000
CY2015Q1 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2015Q1 agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
0
CY2015Q1 agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
4366000
CY2015Q1 agio Vesting Of Restricted Stock Value Increase Decrease
VestingOfRestrictedStockValueIncreaseDecrease
2000
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19009000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0142 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47599 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5396377 shares
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001439222
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M4D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M23D
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
75.17
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7153 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
40.87
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
937665 shares
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.82
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
857000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23594000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-126000
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
190413 shares
CY2016Q1 dei Trading Symbol
TradingSymbol
AGIO
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37864084 shares
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M19D
CY2016Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
31281000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2533000
CY2016Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-2803000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-23198000
CY2016Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
560000
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
407000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22791000
CY2016Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-1411000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
396000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
607000
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
211163000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9107000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5892000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-32729000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
54875000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14828000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1108000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44038000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1108000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9107000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2902000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10837000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
198868000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-293000
CY2016Q1 us-gaap Depreciation
Depreciation
1246000
CY2016Q1 agio Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-8800000
CY2016Q1 agio Collaboration Revenue
CollaborationRevenue
6300000
CY2016Q1 agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
17000
CY2016Q1 agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
8794000

Files In Submission

Name View Source Status
0001193125-16-582822-index-headers.html Edgar Link pending
0001193125-16-582822-index.html Edgar Link pending
0001193125-16-582822.txt Edgar Link pending
0001193125-16-582822-xbrl.zip Edgar Link pending
agio-20160331.xml Edgar Link completed
agio-20160331.xsd Edgar Link pending
agio-20160331_cal.xml Edgar Link unprocessable
agio-20160331_def.xml Edgar Link unprocessable
agio-20160331_lab.xml Edgar Link unprocessable
agio-20160331_pre.xml Edgar Link unprocessable
d162895d10q.htm Edgar Link pending
d162895dex101.htm Edgar Link pending
d162895dex311.htm Edgar Link pending
d162895dex312.htm Edgar Link pending
d162895dex321.htm Edgar Link pending
d162895dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g162895g16r68.jpg Edgar Link pending
g162895g22a78.jpg Edgar Link pending
g162895g43x15.jpg Edgar Link pending
g162895g98z36.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending